Search Patents
  • Growth of foreign cells in fetal animals facilitated by conditional and selective destruction of native host cells
    Patent number: 7626075
    Abstract: Foreign cells can be grown in fetal non-mammalian hosts for the production of transplant organs and tissues, the development of new therapeutic agents, and the production of biological factors and drugs. Tissue-specific injury to fetal host target cells is carried without substantial injury to the maternal host or foreign cells, providing an environment in which the injured tissue can be regenerated with the foreign cells.
    Type: Grant
    Filed: September 17, 2003
    Date of Patent: December 1, 2009
    Assignee: Ximerex, Inc.
    Inventors: William E. Beschorner, Carlos E. Sosa, Scott C. Thompson
  • Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
    Patent number: 6458939
    Abstract: The present invention relates to methods and compositions for the diagnosis, prevention, and treatment of tumors and cancers (e.g., colon cancer) in mammals, e.g., humans. The invention is based on the discovery of genes that ate differentially expressed in tumor cells relative to normal cells. The genes identified can be used diagnostically or as targets for therapy, and can be used to identify compounds useful in the diagnosis, prevention, and therapy of tumors and cancers.
    Type: Grant
    Filed: March 14, 1997
    Date of Patent: October 1, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Andrew W. Shyjan
  • Streptococcus pneumoniae Polynucleotides and Sequences
    Publication number: 20100221287
    Abstract: The present invention provides polynucleotide sequences of the genome of Streptococcus pneumoniae, polypeptide sequences encoded by the polynucleotide sequences, corresponding polynucleotides and polypeptides, vectors and hosts comprising the polynucleotides, and assays and other uses thereof. The present invention further provides polynucleotide and polypeptide sequence information stored on computer readable media, and computer-based systems and methods which facilitate its use.
    Type: Application
    Filed: December 11, 2009
    Publication date: September 2, 2010
    Applicant: Human Genome Sciences, Inc.
    Inventors: Charles A. Kunsch, Gil H. Choi, Patrick J. Dillon, Craig A. Rosen, Steven C. Barash, Michael R. Fannon, Brian A. Dougherty
  • Novel thermostable galactose isomerase and tagatose production thereby
    Publication number: 20030175909
    Abstract: Disclosed are novel thermostable galactose isomerases and production of tagatose using the same. A gene encoding a galactose isomerase with improved thermal stability and reaction equilibrium is screened from natural genetic materials. An expression vector into which the gene is inserted is introduced into bacteria which are then cultured to obtain a thermostable galactose isomerase. In the presence of this enzyme, tagatose is produced from galactose in a yield as high as 46-50% at a temperature as high as 55° C.
    Type: Application
    Filed: August 19, 2002
    Publication date: September 18, 2003
    Inventors: Pil Kim, Sang Hyun Yoon, Myung Ji Seo, Jin Hwan Choi, Hoe Jin Roh
  • Recombinant &agr;-N-acetylgalactosaminidase enzyme and cDNA encoding said enzyme
    Patent number: 6228631
    Abstract: This invention relates to a recombinant enzyme for use in the removal of A antigens from the surface of cells in blood products. Specifically, this invention is directed to a recombinant &agr;-N-acetylgalactosaminidase enzyme from chicken liver, methods of cloning and expressing said recombinant &agr;-N-acetylgalactosaminidase enzyme and a method of removing A antigens from the surface of cells in blood products using said recombinant &agr;-N-acetylgalactosaminidase enzyme.
    Type: Grant
    Filed: April 30, 1998
    Date of Patent: May 8, 2001
    Assignee: New York Blood Center, Inc.
    Inventors: Alex Zhu, Jack Goldstein
  • Use of a baculovirus to express and exogenous gene in a mammalian cell
    Patent number: 5871986
    Abstract: Disclosed is a method of expressing an exogenous gene in a mammalian cell, involving infecting the cell with a baculovirus whose genome carries an exogenous gene, and growing the cell under conditions such that the gene is expressed. Also disclosed is a method of treating a gene deficiency disorder in a mammal by providing to a cell a therapeutically effective amount of a baculovirus whose genome carries an exogenous gene and growing the cell under conditions such that the exogenous gene is expressed in the mammal.
    Type: Grant
    Filed: September 23, 1994
    Date of Patent: February 16, 1999
    Assignee: The General Hospital Corporation
    Inventor: Frederick M. Boyce
  • Nucleic acid and amino acid sequences relating to for diagnostics and therapeutics
    Patent number: 7151171
    Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.
    Type: Grant
    Filed: December 30, 2004
    Date of Patent: December 19, 2006
    Assignee: Sanofi Pasteur Limited/Sanofi Pasteur Limitée
    Inventors: Lynn Doucette-Stamm, David Bush, Qiandong Zeng, Timothy Opperman, Chad Eric Houseweart
  • Nucleic acids encoding kp43 protein and antigenic fragments thereof
    Patent number: 5811284
    Abstract: The invention provides nucleic acids and polypeptides encoding an NK cell surface antigen from a mammal, as well as antibodies that specifically bind the NK cell surface antigen. Methods of using the nucleic acids, polypeptides, and antibodies are provided, including diagnostic kits comprising one or more of these reagents.
    Type: Grant
    Filed: May 20, 1996
    Date of Patent: September 22, 1998
    Assignees: Schering Corporation, Jose Aramburu Beltran, Miguel Lopez-Botet
    Inventors: Chiwen Chang, Jose Aramburu Beltran, Miguel Lopez-Botet, Joseph H. Phillips, Jr., Lewis L. Lanier
  • Variants of corticotropin releasing hormone receptor type 1 and uses thereof
    Publication number: 20030113799
    Abstract: The present invention identifies four new isoforms of human corticotropin releasing hormone receptor type 1 (CRH-R1e, 1f, 1g and 1h) and three new isoforms of mouse corticotropin releasing hormone receptor type 1 (mCRH-R1c, 1e and 1f). The data indicate that polymorphism of CRH-R1 expression is related to anatomic location, skin physiological or pathologic status, specific cell type, external stress (UV), and that cAMP dependent pathways and TPA may regulate CRH-R1.
    Type: Application
    Filed: September 13, 2002
    Publication date: June 19, 2003
    Inventors: Alexander Pisarchik, Andrzej Slominski
  • DNA encoding a Myt1 polypeptide
    Patent number: 6020194
    Abstract: The present invention provides a threonine/tyrosine kinase, Myt1, that phosphorylates the cyclin-dependent kinase, Cdc2, to provide regulation of the cell cycle at the G2/M interphase. Also included are polynucleotides encoding Myt1 polypeptide and antibodies that bind to Myt1. Methods of modulating Myt1 for preventing premature entry of the cell into mitosis or to accelerate entry into mitosis are also provided, as are methods for identifying agents that modulate Myt1.
    Type: Grant
    Filed: October 1, 1997
    Date of Patent: February 1, 2000
    Assignee: California Institute of Technology
    Inventors: Paul R. Mueller, Thomas R. Coleman, Akiko Kumagai, William G. Dunphy
  • Utrophin gene expression
    Patent number: 6518413
    Abstract: Nucleic acid from which a polypeptide with utrophin function can be expressed, especially mini-genes and chimaeric constructs. Expression significantly decreases the severity of the dystrophic muscle phenotype in an animal model, indicating usefulness in treatment of muscular dystrophy. The nucleic acid and encoded polypeptides are also useful in screening for substances to modulate utrophin binding to actin and/or the dystrophin protein complex.
    Type: Grant
    Filed: July 14, 1998
    Date of Patent: February 11, 2003
    Assignee: Medical Research Council
    Inventors: Jonathon M. Tinsley, Kay E. Davies
  • Nucleic and proteinic acids corresponding to human gene ABC1
    Publication number: 20040185456
    Abstract: The invention relates to nucleic acids corresponding to different exons and introns of gene ABC1 which is shown to be a gene causing pathologies linked to cholesterol metabolism dysfunction causing diseases such as atherosclerosis, more particularly perturbation of reverse cholesterol transport and more particularly the FHD's such as Tangier Disease
    Type: Application
    Filed: June 18, 2003
    Publication date: September 23, 2004
    Applicant: Aventis Pharma S.A.
    Inventors: Patrice Denefle, Marie-Francoise Rosier-Montus, Isabelle Arnould-Reguigne, Catherine Prades, Laurent Naudin, Cendrine Lemoine, Nicolas Duverger, Stephan Rust, Gerd Assmann, Harald Funke, H. Bryan Brewer
  • Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
    Patent number: 11919946
    Abstract: The present invention provides compositions and methods for regulating the specificity and activity of T cells. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “KIR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: March 5, 2024
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Michael C. Milone, Enxiu Wang
  • eNOS mutations useful for gene therapy and therapeutic screening
    Publication number: 20040253685
    Abstract: The present invention relates to new NOS variants or mutants which contain structural alterations in the site of Akt dependent phosphorylation. The altered NOS proteins or peptides, especially the human eNOS proteins or peptides, Akt proteins or polypeptides and their encoding nucleic acid molecules are useful as gene therapy agents for the treatment of diseases including post angioplasty restenosis, hypertension, atherosclerosis, heart failure, diabetes and diseases with defective angiogenesis. NOS proteins and peptides are also useful in methods of screening for agents which modulate NOS activity.
    Type: Application
    Filed: July 12, 2004
    Publication date: December 16, 2004
    Applicant: Yale University
    Inventor: William C. Sessa
  • A-myb null mutant transgenic mice
    Patent number: 6410825
    Abstract: Transgenic non-human animals and transgenic non-human stem cells are described having a functionally disrupted A-myb locus. Targeting constructs used to produce such transgenic stem cells and animals, and methods and targeting constructs for inactivating an endogenous A-myb gene locus, are also provided. Also provided are methods for generating transgenic sperm and transgenic nonhuman animals harboring a desired transgene.
    Type: Grant
    Filed: March 22, 2000
    Date of Patent: June 25, 2002
    Assignee: Temple University-Of The Commonwealth System of Higher Education
    Inventors: Antonio Toscani, Kimi Hatton, E. Premkumar Reddy
  • Gene encoding a DNA repair enzyme and methods of use thereof
    Patent number: 7491807
    Abstract: An isolated nucleic acid molecule encoding a human DNA repair enzyme, MED1, is disclosed. Like other mismatch repair genes which are mutated in certain cancers, MED1, encoding nucleic acids, proteins and antibodies thereto may be used to advantage in genetic or cancer screening assays. MED1, which recognizes and cleaves DNA, may also be used for the diagnostic detection of mutations and genetic variants.
    Type: Grant
    Filed: April 24, 2007
    Date of Patent: February 17, 2009
    Assignee: Fox Chase Cancer Center
    Inventor: Alfonso Bellacosa
  • Vascular endothelial cell growth inhibitor, VEGI-192a
    Patent number: 7750133
    Abstract: This invention discloses two new VEGI isoforms named VEGI-192a and VEGI-192b consisting of 192 amino acid residues. These isoforms show endothelial cell-specific expression and share a C-terminal 151-residues segment with the previously described VEGI-174 and VEGI-251. Methods of using these isoforms of VEGI in diagnosing, screening agonist and antagonist of the isoforms, and treating various angiogenesis-related diseases are also disclosed.
    Type: Grant
    Filed: December 6, 2007
    Date of Patent: July 6, 2010
    Assignee: Georgetown University
    Inventors: Luyuan Li, Hongguang Pan
  • Engineering intracellular sialylation pathways
    Publication number: 20020142386
    Abstract: Methods for manipulating carbohydrate processing pathways in cells of interest are provided. Methods are directed at manipulating multiple pathways involved with the sialylation reaction by using recombinant DNA technology and substrate feeding approaches to enable the production of sialylated glycoproteins in cells of interest. These carbohydrate engineering efforts encompass the implementation of new carbohydrate bioassays, the examination of a selection of insect cell lines and the use of bioinformatics to identify gene sequences for critical processing enzymes. The compositions comprise cells of interest producing sialylated glycoproteins. The methods and compositions are useful for heterologous expression of glycoproteins.
    Type: Application
    Filed: August 16, 2001
    Publication date: October 3, 2002
    Inventors: Michael J. Betenbaugh, Shawn Lawrence, Yuan C. Lee, Timothy A. Coleman
  • Camp-responsive transcriptional enhancer binding protein
    Patent number: 6251667
    Abstract: This invention is directed toward the characterization and cloning of a cAMP-responsive transcription enhancer binding protein (CREB). This protein, CREB, is a transcriptional activator which activates transcription in eukaryotic cells. This CREB protein can be used to increase or decrease production of proteins by stimulating expression of a recombinant gene that is operably-linked to the CRE enhancer element and responsive to cAMP.
    Type: Grant
    Filed: February 19, 1999
    Date of Patent: June 26, 2001
    Assignee: The General Hospital Corporation
    Inventors: Joel F. Habener, James P. Hoeffler
  • Polynucleotide encoding a novel methionine aminopeptidase, protease-39
    Publication number: 20030204070
    Abstract: The present invention provides novel polynucleotides encoding Protease-39 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel Protease-39 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Application
    Filed: January 23, 2003
    Publication date: October 30, 2003
    Inventors: Jian Chen, John N. Feder, Thomas C. Nelson, Donna A. Bassolino, Stanley R. Krystek, Joseph Naglich